Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Exelixis Hits Blockbuster Status

TheMotleyFool

0 0

Sales of Exelixis' (NASDAQ: EXEL) cabozantinib franchise, which includes Cabometyx for kidney and liver cancers and Cometriq for thyroid cancer, broke $250 million globally in the second quarter, making the drug a blockbuster, typically defined as $1 billion in annual sales.

Metric

Q2 2019

Quelle Fool.com

Like: 0

EXEL

Share